

# Bereskin & Parr

INTELLECTUAL PROPERTY LAW

Scotia Plaza, 40 King Street West, 40th Floor, Toronto, Ontario, Canada M5H 3Y2

Tel: 416.364.7311 Fax: 416.361.1398 [www.bereskinparr.com](http://www.bereskinparr.com)

TORONTO MISSISSAUGA WATERLOO MONTREAL

## FAX TRANSMITTAL

TO: Ja-Na Hines  
FIRM: United States Patent & Trademark Office  
FROM: Micheline Gravelle  
FILE #: 7841-89  
LAWYER #: 193

DATE: 07/18/05 FAX #: 571-273-0859 PAGES: (including cover sheet)

COMMENTS:

Dear Ja-Na,

The present facsimile is further to our telephone conversation of July 18, 2005.

As you requested, I enclose a draft response to the Advisory Action. Please advise if the amendment is suitable in order to have the case proceed to allowance.

Yours truly,



Micheline Gravelle

If transmission is interrupted or of poor quality, please notify us immediately by calling Sarah Morrison at 416 957-1600 ex. 6331.

**CONFIDENTIAL**

This communication may contain information that is privileged or confidential and is intended only for the use of the individual to whom it is addressed. Any other distribution, copying or disclosure is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us by mail. Thank you.

Appl. No. 09/402,446  
DRAFT Response July 18, 2005

Confirmation No.: 5954

Appl. No : 09/402,446  
Applicants : Hugh W. Price and B. Michael R. Woloski  
Filed : January 18, 2000  
Title : Intravenous Immune Globulin Formulations Containing A Non-Ionic Surface Active Agent with Improved Pharmacokinetic Properties  
TC./A.U. : 1645  
Examiner : Ja-Na Hines  
  
Docket No. : 7841-89  
Customer No. : 001059

Honorable Commissioner for Patents  
P. O. Box 1450  
Alexandria, Virginia 22313-1450

**DRAFT RESPONSE**

Sir:

This is in response to the advisory action that was mailed May 31, 2005. The six-month deadline for responding to the final office action mailed January 24, 2005 expires July 24, 2005.

**Amendments** to the claims begin on page 2 of this paper.

**Remarks** begin on page 8 of this paper.